Compare GE Aerospace (GE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs TG Therapeutics Inc — how do they compare? GE Aerospace trades at $308.4 (market cap $317.10B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: GE Aerospace is far larger — about 38.9× TG Therapeutics Inc's market cap, and GE Aerospace pays a 0.62% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and TG Therapeutics Inc for 16 Days on average.
| GE | TGTX | |
|---|---|---|
Market Cap | $317.10B | $8.16B |
Volume | 6,320,106 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $381.22 | $59.06 |
52-Week Low | $273.25 | $26.94 |
Typical Hold Time | 111 Days | 16 Days |
Enterprise Value | $326.91B | $8.37B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $303.62, down 1.86% amid broader market weakness, with technical indicators showing bearish momentum despite strong fundamentals. The company has consistently beaten earnings expectations with Q2 2026 EPS of $2.02 exceeding estimates, while revenue growth accelerated to $45.86 billion in 2025. Recent news highlights GE's $12 billion acquisition of Consolidated Precision Products to address supply chain constraints in jet engine components.
The stock presents a compelling value opportunity with a 35% upside to the consensus price target of $409.60, supported by 24 buy ratings and no sell recommendations. However, high valuation multiples and integration risks from the CPP acquisition warrant caution. Strong free cash flow generation and shareholder returns through dividends and buybacks provide downside protection.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
